Stockscreener 앱 받기
2.25
0.45%
0.010
시장 영업 전:
2.39
0.14
+6.22%
전일 마감가:
$2.24
열려 있는:
$2.26
하루 거래량:
3.06M
Relative Volume:
2.21
시가총액:
$160.35M
수익:
-
순이익/손실:
$-292.19M
주가수익비율:
-0.4956
EPS:
-4.54
순현금흐름:
$-208.41M
1주 성능:
-14.93%
1개월 성능:
-25.00%
6개월 성능:
-39.19%
1년 성능:
-82.54%
1일 변동 폭
$2.19
$2.39
1주일 범위
$2.16
$2.93
52주 변동 폭
$2.16
$18.07
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
명칭
Zentalis Pharmaceuticals Inc
전화
(858) 263-4333
주소
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
ZNTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.25 | 160.35M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-12 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2024-06-20 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-06-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2024-06-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 개시 | Cowen | Outperform |
| 2022-04-06 | 개시 | Wells Fargo | Overweight |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-29 | 개시 | Oppenheimer | Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-01-20 | 개시 | Wedbush | Outperform |
| 2020-09-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Guggenheim | Buy |
| 2020-04-28 | 개시 | Jefferies | Buy |
| 2020-04-28 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 개시 | SVB Leerink | Outperform |
모두보기
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Barclays PLC - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Down 17.5% in December - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update - MarketBeat
Why Zentalis Pharma Is Worth Watching - RTTNews
Zentalis stock plunges to 52-week low of $2.64 amid market challenges - Investing.com Canada
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Zentalis Pharmaceuticals, Inc. Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - Marketscreener.com
Zentalis Gets FDA Fast-Track Designation for Azenosertib - MarketWatch
Zentalis Pharmaceuticals Announces Azenosertib Fast Track - GlobeNewswire
Zentalis' Cancer Drug Azenosertib Receives FDA Fast Track Status for Ovarian Cancer Treatment - StockTitan
Geode Capital Management LLC Has $4.76 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Barclays PLC Buys 11,748 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Jane Street Group LLC Sells 11,796 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals chief scientific officer sells $13,762 in stock By Investing.com - Investing.com South Africa
Mark Lackner Sells 4,411 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock - MarketBeat
Zentalis Pharmaceuticals chief scientific officer sells $13,762 in stock - Investing.com India
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Awards Stock Options to New Hires Under Incentive Plan - StockTitan
State Street Corp Sells 1,805,779 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Analysts - Defense World
ZNTLZentalis Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Athersys (NASDAQ:ATHX) vs. Zentalis Pharmaceuticals (NASDAQ:ZNTL) Head to Head Review - Defense World
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - Kilgore News Herald
Zentalis Pharmaceuticals expands leadership team - Investing.com India
Zentalis Pharmaceuticals Appoint Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer - citybiz
Zentalis Pharmaceuticals Announces Key Management Appointments - GlobeNewswire
Zentalis Pharmaceuticals Strengthens Leadership Team with Strategic Biotech Executive Appointments - StockTitan
The time has not yet come to remove your chips from the table: Zentalis Pharmaceuticals Inc (ZNTL) - SETE News
Fmr LLC Has $18.68 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Osteosarcoma Market expected to rise | AlaMab Therapeutics, Zentalis Pharmaceuticals, Merck Eprova, Eisai Co Ltd., expected to drive Osteosarcoma market - Barchart
Osteosarcoma Market expected to rise | AlaMab Therapeutics, - openPR
Verition Fund Management LLC Buys 951,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
Zentalis Pharmaceuticals Grants 4.5M Stock Options to New CEO, CMO & Employees | ZNTL Stock News - StockTitan
ZNTL (Zentalis Pharmaceuticals) EBITDA : $-207.96 Mil (TTM As of Sep. 2024) - GuruFocus.com
Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $10.00 - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Sees Significant Drop in Short Interest - MarketBeat
Nano Dimension Leads 3 US Penny Stocks To Consider - Simply Wall St
Primecap Management Co. CA Boosts Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat
What is HC Wainwright’s Forecast for ZNTL Q3 Earnings? - Defense World
Zentalis Pharmaceuticals Inc (ZNTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):